Lifesci Capital Brokers Cut Earnings Estimates for Neurogene

Neurogene Inc. (NASDAQ:NGNE) – Equities researchers at Lifesci Capital cut their Q2 2026 earnings per share estimates for Neurogene in a research note issued to investors on Wednesday, May 13th. Lifesci Capital analyst P. Dolezal now anticipates that the company will post earnings per share of ($1.41) for the quarter, down from their previous estimate of ($1.28). Lifesci Capital currently has a “Outperform” rating and a $50.00 target price on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($5.35) per share. Lifesci Capital also issued estimates for Neurogene’s Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.01) EPS and FY2026 earnings at ($4.88) EPS.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.09).

Several other equities analysts have also commented on NGNE. Canaccord Genuity Group cut their price target on Neurogene to $180.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Guggenheim started coverage on Neurogene in a research note on Tuesday, April 28th. They issued a “buy” rating and a $69.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $67.00.

Neurogene Trading Down 4.1%

Shares of Neurogene stock opened at $31.27 on Friday. The firm has a market cap of $494.07 million, a P/E ratio of -6.87 and a beta of 1.69. Neurogene has a 12 month low of $14.65 and a 12 month high of $37.27. The stock’s fifty day moving average price is $24.07 and its 200-day moving average price is $22.10.

Insider Activity

In other Neurogene news, CFO Christine Mikail Cvijic sold 9,600 shares of Neurogene stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $31.25, for a total value of $300,000.00. Following the transaction, the chief financial officer owned 93,640 shares in the company, valued at $2,926,250. The trade was a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Cobb sold 6,797 shares of Neurogene stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $20.81, for a total value of $141,445.57. Following the completion of the transaction, the insider owned 30,497 shares in the company, valued at $634,642.57. This trade represents a 18.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 20,442 shares of company stock worth $525,622 in the last quarter. 11.64% of the stock is owned by insiders.

Hedge Funds Weigh In On Neurogene

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its stake in shares of Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after acquiring an additional 978 shares during the last quarter. Daiwa Securities Group Inc. purchased a new stake in shares of Neurogene during the fourth quarter worth about $66,000. PNC Financial Services Group Inc. grew its stake in shares of Neurogene by 24.7% during the third quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock worth $88,000 after acquiring an additional 1,000 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after acquiring an additional 1,059 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Neurogene during the fourth quarter worth about $165,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.